Doctor Arcomita Doina

07/01/2026

Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population.

A new Review summarises recent breakthroughs, potential future developments, and discusses the key challenges around selecting appropriate treatment avenues for patients.

Read in full via the link in comments 💬

👇 Figure: Summary of mechanisms of action targeted for MASH therapy.

04/01/2026

and effectively target and GIP receptors for obesity treatment, with future therapies exploring further receptor targeting for improved outcomes.

https://ja.ma/45Dk5Um

27/12/2025

17/12/2025

11/10/2025

50 mg of oral daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or , with or without type 2 . https://ja.ma/47fYGll

19/09/2025

Integrating lifestyle factors like diet and physical activity with receptor agonists is essential for managing symptoms, maintaining nutrition, preserving lean mass, and promoting regular physical activity. https://ja.ma/4n9MFmH

29/07/2025

Physicians detail five practical measures to optimize GLP-1 therapy and prevent muscle loss in patients undergoing weight reduction. http://ms.spr.ly/6187sHcwf

25/06/2025

Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach the full 2.4 mg weekly dose — according to new data from the SELECT trial. http://ms.spr.ly/6186SbBuy

08/06/2025

Continuing metformin throughout the first trimester in women with polycystic o***y syndrome shows potential to reduce miscarriage risk and increase clinical pregnancy rates. http://ms.spr.ly/6184SW4Yp